Accuray Incorporated (ARAY) stock profile

Frequently asked questions

What does Accuray Incorporated (ARAY) do?

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used to treat primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy System, including the Radixact System, which enables integrated radiation treatment planning, delivery, and data management, allowing clinicians to treat approximately 50 patients per day with ultra-precise care. Additional offerings include the iDMS data management system and the Accuray precision treatment planning system, both fully integrated treatment planning and data management platforms. The company also provides post-contract customer support, installation, training, and other professional services. It markets its products primarily through direct sales to hospitals and stand-alone treatment facilities, as well as through sales agents and group purchasing organizations in the United States, and through distributors and sales agents internationally. Accuray was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Where is ARAY stock listed?

Accuray Incorporated trades under the ticker ARAY on NASDAQ.

How can I research ARAY's financials and filings?

Vantafin provides Accuray Incorporated's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ARAY profile.